<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "2: risks discussed", fill: "#3c1414"},
{source: "2: risks discussed", target: "2: filings with", fill: "#3c1414"},
{source: "2: filings with", target: "2: Securities and Exchange Commission ", fill: "#3c1414"},
{source: "2: Securities and Exchange Commission ", target: "2: impact on", fill: "#3c1414"},
{source: "2: impact on", target: "2: financial condition", fill: "#3c1414"},
{source: "2: financial condition", target: "2: operations", fill: "#3c1414"},
{source: "2: risks discussed", target: "4: success will depend", fill: "#7fffd4"},
{source: "4: success will depend", target: "4: heart valve", fill: "#7fffd4"},
{source: "4: heart valve", target: "4: United States ", fill: "#7fffd4"},
{source: "4: United States ", target: "4: largest revenue market", fill: "#7fffd4"},
{source: "4: largest revenue market", target: "4: heart valves", fill: "#7fffd4"},
{source: "4: success will depend", target: "32: significant competition", fill: "#654321"},
{source: "32: significant competition", target: "32: sales personnel", fill: "#654321"},
{source: "32: sales personnel", target: "32: independent", fill: "#654321"},
{source: "32: independent", target: "32: manufacturing representatives with", fill: "#654321"},
{source: "32: manufacturing representatives with", target: "32: advanced sales skills", fill: "#654321"},
{source: "32: significant competition", target: "68: competitors", fill: "#df00ff"},
{source: "68: competitors", target: "68: ability due", fill: "#df00ff"},
{source: "68: ability due", target: "68: carbon manufacturing facilities", fill: "#df00ff"},
{source: "68: carbon manufacturing facilities", target: "68: manufacture", fill: "#df00ff"},
{source: "68: manufacture", target: "68: heart valve", fill: "#df00ff"},
{source: "68: heart valve", target: "68: lower cost than", fill: "#df00ff"},
{source: "68: competitors", target: "101: manufacture", fill: "#3f00ff"},
{source: "101: manufacture", target: "101: mechanical heart valves entails significant risk", fill: "#3f00ff"},
{source: "101: mechanical heart valves entails significant risk", target: "101: product liability", fill: "#3f00ff"},
{source: "101: product liability", target: "101: product recalls", fill: "#3f00ff"},
{source: "101: manufacture", target: "START_HERE", fill: "#3f00ff"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Independent Power Producers and Energy Traders</td>
    </tr>
    <tr>
      <td>Automobiles and Components</td>
    </tr>
    <tr>
      <td>Electrical Components and Equipment</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Health Care Supplies</td>
    </tr>
    <tr>
      <td>Health Care</td>
    </tr>
    <tr>
      <td>Health Care Equipment and Services</td>
    </tr>
    <tr>
      <td>Managed Health Care</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Policy</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_(mathematics)">Operation (mathematics)</a></td>
      <td>In mathematics, an operation is a function which takes zero or more input values (called operands) to a well-defined output value. The number of operands (also known as arguments) is the arity of the operation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Heart_valve">Heart valve</a></td>
      <td>A heart valve is a one-way valve that allows blood to flow in one direction through the chambers of the heart. Four valves are  usually present in a mammalian heart and together they determine the pathway of blood flow through the heart.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Artificial_heart_valve">Artificial heart valve</a></td>
      <td>An artificial heart valve is a one-way valve implanted into a person's heart to replace a heart valve that is not functioning properly (valvular heart disease). Artificial heart valves can be separated into three broad classes: mechanical heart valves, bioprosthetic tissue valves and engineered tissue valves.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Valvular_heart_disease">Valvular heart disease</a></td>
      <td>Valvular heart disease is any cardiovascular disease process involving one or more of the four valves of the heart (the aortic and mitral valves on the left side of heart and the pulmonic and tricuspid valves on the right side of heart). These conditions occur largely as a consequence of aging, but may also be the result of congenital (inborn) abnormalities or specific disease or physiologic processes including rheumatic heart disease and pregnancy.Anatomically, the valves are part of the dense connective tissue of the heart known as the cardiac skeleton and are responsible for the regulation of blood flow through the heart and great vessels.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Mitral_valve">Mitral valve</a></td>
      <td>The mitral valve (), also known as the bicuspid valve or left atrioventricular valve, is one of the four heart valves. It has two cusps or flaps and lies between the left atrium and the left ventricle of the heart.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Heart_valve_repair">Heart valve repair</a></td>
      <td>Heart valve repair is a cardiac surgery procedure, carried out to repair one or more faulty heart valves. In some valvular heart diseases repair where possible is preferable to valve replacement.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Heart">Heart</a></td>
      <td>A head is the part of an organism which usually includes the ears, brain, forehead, cheeks, chin, eyes, nose, and mouth, each of which aid in various sensory functions such as sight, hearing, smell, and taste, respectively. Some very simple animals may not have a head, but many bilaterally symmetric forms do, regardless of size.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Percutaneous_aortic_valve_replacement">Percutaneous aortic valve replacement</a></td>
      <td>Percutaneous aortic valve replacement (PAVR), also known as percutaneous aortic valve implantation (PAVI), transcatheter aortic valve implantation (TAVI) or transcatheter aortic valve replacement (TAVR), is the replacement of the aortic valve of the heart through the blood vessels (as opposed to valve replacement by open heart surgery). The replacement valve is delivered via one of several access methods: transfemoral (in the upper leg), transapical (through the wall of the heart), subclavian (beneath the collar bone), direct aortic (through a minimally invasive surgical incision into the aorta), and transcaval (from a temporary hole in the aorta near the navel through a vein in the upper leg), among others.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States">United States</a></td>
      <td>The United States of America (U.S.A. or USA), commonly known as the United States (U.S. or US) or America, is a country primarily located in North America. It consists of 50 states, a federal district, five major unincorporated territories, 326 Indian reservations, and nine minor outlying islands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_states_and_territories_of_the_United_States">List of states and territories of the United States</a></td>
      <td>The United States of America is a federal republic consisting of 50 states, a federal district (Washington, D.C., the capital city of the United States), five major territories, and various minor islands. The 48 contiguous states and Washington, D.C., are in North America between Canada and Mexico.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/President_of_the_United_States">President of the United States</a></td>
      <td>The president of the United States (POTUS) is the head of state and head of government of the United States of America. The president directs the executive branch of the federal government and is the commander-in-chief of the United States Armed Forces.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_Congress">United States Congress</a></td>
      <td>The United States Congress is the legislature of the federal government of the United States. It is bicameral, being composed of a lower body, the House of Representatives, and an upper body, the Senate.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_Navy">United States Navy</a></td>
      <td>The United States Navy (USN) is the maritime service branch of the United States Armed Forces and one of the eight uniformed services of the United States. It is the largest and most powerful navy in the world, with the estimated tonnage of its active battle fleet alone exceeding the next 13 navies combined, including 11 U.S. allies or partner nations as of 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Republican_Party_(United_States)">Republican Party (United States)</a></td>
      <td>The Republican Party, also referred to as the GOP ("Grand Old Party"), is one of the two major contemporary political parties in the United States, along with its main historic rival, the Democratic Party.\nThe GOP was founded in 1854 by anti-slavery activists who opposed the Kansas–Nebraska Act, which allowed for the potential expansion of chattel slavery into the western territories.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_presidents_of_the_United_States">List of presidents of the United States</a></td>
      <td>The president of the United States is the head of state and head of government of the United States, indirectly elected to a four-year term by the American people through the Electoral College. The office holder leads the executive branch of the federal government and is the commander-in-chief of the United States Armed Forces.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_Marine_Corps">United States Marine Corps</a></td>
      <td>The United States Marine Corps (USMC), also referred to as the United States Marines, is the maritime land force service branch of the United States Armed Forces responsible for conducting expeditionary and amphibious operations through combined arms, implementing its own infantry, artillery, aerial, and special operations forces. The U.S. Marine Corps is one of the eight uniformed services of the United States.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_dollar">United States dollar</a></td>
      <td>The United States dollar (symbol: $; code: USD; also abbreviated US$ or U.S. Dollar, to distinguish it from other dollar-denominated currencies; referred to as the dollar, U.S. dollar, American dollar, or colloquially buck) is the official currency of the United States and several other countries. The Coinage Act of 1792 introduced the U.S. dollar at par with the Spanish silver dollar, divided it into 100 cents, and authorized the minting of coins denominated in dollars and cents.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Aortic_valve_replacement">Aortic valve replacement</a></td>
      <td>Aortic valve replacement is a procedure whereby the failing aortic valve of a patient's heart is replaced with an artificial heart valve. The aortic valve may need to be replaced because:\n\nThe valve is leaky (aortic insufficiency, also known as aortic regurgitation)\nThe valve is narrowed and doesn't open fully (aortic stenosis)Current methods for aortic valve replacement include open-heart surgery, termed minimally invasive cardiac surgery (MICS) or surgical aortic valve replacement (SAVR) and transcatheter aortic valve replacement (TAVR).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Grasshopper_Manufacture">Grasshopper Manufacture</a></td>
      <td>Grasshopper Manufacture Inc. (株式会社グラスホッパー・マニファクチュア, Kabushiki Gaisha Gurasuhoppā Manifakuchua) is a Japanese video game developer founded on March 30, 1998 by Goichi Suda.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacture_d'horlogerie">Manufacture d'horlogerie</a></td>
      <td>Manufacture d'horlogerie (meaning "watchmaking manufacturer") is a French language term of horology that has also been adopted in the English language as a loanword. In horology, the term is usually encountered in its abbreviated form manufacture.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Build-on-demand">Build-on-demand</a></td>
      <td>Build-on-demand or manufacturing on demand (MOD) refers to a manufacturing process where goods are produced only when or as they are required. This allows scalability and adjustable assemblies depending on the current needs of the part requestor or client.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Computer-aided_manufacturing">Computer-aided manufacturing</a></td>
      <td>Computer-aided manufacturing (CAM) also known as computer-aided modeling or computer-aided machining is the use of software to control machine tools in the manufacturing of work pieces. This is not the only definition for CAM, but it is the most common; CAM may also refer to the use of a computer to assist in all operations of a manufacturing plant, including planning, management, transportation and storage.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Product_liability">Product liability</a></td>
      <td>Product liability is the area of law in which manufacturers, distributors, suppliers, retailers, and others who make products available to the public are held responsible for the injuries those products cause. Although the word "product" has broad connotations, product liability as an area of law is traditionally limited to products in the form of tangible personal property.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Legal_liability">Legal liability</a></td>
      <td>In law, liable means  "responsible or answerable in law; legally obligated". Legal liability concerns both civil law and criminal law and can arise from various areas of law, such as contracts, torts, taxes, or fines given by government agencies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Strict_liability">Strict liability</a></td>
      <td>In  criminal  and  civil law, strict liability is a standard of liability under which a person is legally responsible for the consequences flowing from an activity even in the absence of fault or criminal intent on the part of the defendant.\nUnder the strict liability law, if the defendant possesses anything that is inherently dangerous, as specified under the "ultrahazardous" definition, the defendant is then strictly liable for any damages caused by such possession, no matter how careful the defendant is safeguarding them.In the field of torts, prominent examples of strict liability may include product liability, abnormally dangerous activities (e.g., blasting), intrusion onto another's land by livestock, and ownership of wild animals.Other than activities specified above (like ownership of wild animals, etc), US courts also consider the following activities as "ultrahazardous":\nstoring flammable liquids in quantity in an urban area\npile driving\nblasting\ncrop dusting\nfumigation with cyanide gas\nemission of noxious fumes by a manufacturing plant located in a settled area\nlocating oil wells or refineries in populated communities\ntest firing solid-fuel rocket motors.On the other hand, US courts rule the following activities as not "ultrahazardous": parachuting, drunk driving, maintaining power lines, and letting water escape from an irrigation ditch.Traditional criminal offenses that require no element of intent (mens rea) include statutory rape and felony murder.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Professional_liability_insurance">Professional liability insurance</a></td>
      <td>Professional liability insurance (PLI), also called professional indemnity insurance (PII) but more commonly known as errors &amp; omissions (E&amp;O) in the US, is a form of liability insurance which helps protect professional advice- and service-providing individuals and companies from bearing the full cost of defending against a negligence claim made by a client, and damages awarded in such a civil lawsuit. \nThe coverage focuses on alleged failure to perform on the part of, financial loss caused by, and error or omission in the service or product sold by the policyholder.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Product_Liability_Directive_1985">Product Liability Directive 1985</a></td>
      <td>The Product Liability Directive 85/374/EEC is a directive of the Council of the European Communities (now the European Union) which created a regime of strict liability for defective products applicable in all member states of the European Union, the other EEA members (Iceland, Liechtenstein and Norway) and the United Kingdom.\n\n\n== Background ==\nThe Council adopted a resolution in 1975 for a preliminary programme on consumer protection and information technology.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Self-driving_car_liability">Self-driving car liability</a></td>
      <td>Increases in the use of autonomous car technologies (e.g., advanced driver-assistance systems) are causing incremental shifts in the responsibility of driving, with the primary motivation of reducing the frequency of traffic collisions. Liability for incidents involving self-driving cars is a developing area of law and policy that will determine who is liable when a car causes physical damage to persons or property.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Tort_reform">Tort reform</a></td>
      <td>Tort reform refers to changes in the civil justice system in common law countries that aim to reduce the ability of plaintiffs to bring tort litigation (particularly actions for negligence) or to reduce damages they can receive. Such changes are generally justified under the grounds that litigation is an inefficient means to compensate plaintiffs; that tort law permits frivolous or otherwise undesirable litigation to crowd the court system; or that the fear of litigation can serve to curtail innovation, raise the cost of consumer goods or insurance premiums for suppliers of services (e.g.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Automobile_products_liability">Automobile products liability</a></td>
      <td>When a person makes a claim for personal injury damages that have resulted from the presence of a defective automobile or component of an automobile, that person asserts a product liability claim. That claim may be against the automobile's manufacturer, the manufacturer of a component part or system, or both, as well as potentially being raised against companies that distributed, sold or installed the part or system that is alleged to be defective.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Any of the <font color="blue">risks discussed</font> below, or elsewhere in  this Form 10-K or our other <font color="blue">filings with</font> the Securities and Exchange Commission,  could have a material <font color="blue">impact on</font> our business, <font color="blue">financial condition</font> or results of  <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font>risks and <font color="blue">uncertainties</font> not <font color="blue">presently known</font> to us or that  we currently believe to be <font color="blue">immaterial may also impair</font> our business <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>IF OUR HEART VALVE DOES NOT ACHIEVE WIDESPREAD MARKET ACCEPTANCE IN THE UNITED  STATES, OUR OPERATING RESULTS WILL BE HARMED AND WE MAY NOT ACHIEVE  PROFITABILITY    Our <font color="blue">success will depend</font>, in large part, on the medical communityapstas acceptance of  the ATS <font color="blue">heart valve</font> in the <font color="blue">United States</font>, which is the <font color="blue">largest revenue market</font> in  the world for <font color="blue">heart valve</font>s</td>
    </tr>
    <tr>
      <td>The US medical communityapstas acceptance <font color="blue">of the ATS </font> <font color="blue">heart valve</font> will depend upon our ability to <font color="blue">demonstrate</font> the safety and efficacy,  advantages, long-term clinical performance and cost-effectiveness <font color="blue">of the ATS </font> <font color="blue">heart valve</font> as compared to other prosthetic <font color="blue">heart valve</font>s</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot predict</font>  whether the US <font color="blue">medical community will accept</font> the ATS <font color="blue">heart valve</font> or, if  accepted, the extent of its use</td>
    </tr>
    <tr>
      <td>Negative publicity resulting <font color="blue">from isolated</font>  <font color="blue">incidents involving</font> the ATS <font color="blue">heart valve</font> or other prosthetic <font color="blue">heart valve</font>s could  have a <font color="blue"><font color="blue">significant</font> adverse</font> effect on the <font color="blue">overall acceptance</font> of our <font color="blue">heart valve</font></td>
    </tr>
    <tr>
      <td>If we <font color="blue">encounter <font color="blue">difficult</font>ies</font> developing a market for the ATS <font color="blue">heart valve</font> in the  <font color="blue">United States</font>, we may not be able to increase our <font color="blue">revenue enough</font> to achieve  <font color="blue">profitability</font> and our business and results of <font color="blue">operations</font> will be seriously  harmed</td>
    </tr>
    <tr>
      <td>WE CURRENTLY RELY ON THE ATS HEART VALVE AS OUR PRIMARY SOURCE OF REVENUE IF WE  ARE NOT SUCCESSFUL IN SELLING THIS PRODUCT, OUR OPERATING RESULTS WILL BE  HARMED    While we commenced marketing additional products during 2005 that totaled 10prca of  <font color="blue">net revenues</font> for the year ended <font color="blue">December </font>31, 2005, there can be no assurance  that these <font color="blue">new products will decrease</font> our <font color="blue">dependence on</font> the sales of mechanical  <font color="blue">heart valve</font>s</td>
    </tr>
    <tr>
      <td><font color="blue">Increasing </font><font color="blue">revenues from new products cannot</font> be guaranteed</td>
    </tr>
    <tr>
      <td>Clinical testing and the <font color="blue">approval process itself</font> are very  expensive and can take many years</td>
    </tr>
    <tr>
      <td>Therefore, we do not expect to be in a  position to <font color="blue">sell additional products</font> in the <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>Adverse rulings  by <font color="blue">regulatory</font> authorities, <font color="blue">product <font color="blue">liability</font></font> lawsuits, the failure to achieve  widespread US <font color="blue">market acceptance</font>, the loss of <font color="blue">market acceptance</font> outside of the  <font color="blue">United States</font>, or other <font color="blue">adverse publicity may <font color="blue">significant</font>ly</font> and <font color="blue"><font color="blue">adversely</font> affect</font>  our sales <font color="blue">of the ATS </font><font color="blue">heart valve</font>, and, as a result, would <font color="blue"><font color="blue">adversely</font> affect</font> our  business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">THE ANTICIPATED BENEFITS OF ACQUIRING </font>3F THERAPEUTICS MAY NOT BE REALIZED    ATS and 3F entered into the merger <font color="blue">agreement</font> with the <font color="blue">expectation</font> that the  merger will result in various benefits, including, among others, benefits  relating to an expanded <font color="blue">heart valve</font> product line, enhanced revenues, a  <font color="blue">strengthened market position</font> for ATS in the <font color="blue">heart valve</font> industry, cross selling  opportunities, <font color="blue">technology</font>, cost savings and operating <font color="blue">efficiencies</font></td>
    </tr>
    <tr>
      <td><font color="blue">Achieving  </font>the anticipated benefits of the merger is subject to a number of <font color="blue">uncertainties</font>,  including whether 3Fapstas development-stage products are <font color="blue">ultimately marketable</font>,  whether ATS integrates 3F in an <font color="blue">efficient</font> and <font color="blue">effective manner</font>, and general  <font color="blue">competitive factors</font> in the marketplace</td>
    </tr>
    <tr>
      <td>Failure to achieve these anticipated  benefits could result in increased costs, <font color="blue">decreases</font> in the amount of expected  revenues and diversion of <font color="blue">management</font>apstas time and energy and <font color="blue">could <font color="blue">materially</font></font>  impact ATSapstas business, <font color="blue">financial condition</font> and operating results</td>
    </tr>
    <tr>
      <td><font color="blue">ATS MEDICAL MAY HAVE DIFFICULTY INTEGRATING </font>3F THERAPEUTICS AND MAY INCUR  SUBSTANTIAL COSTS IN CONNECTION WITH THE INTEGRATION    Integrating 3Fapstas <font color="blue">operations</font> into ATSapstas business will be a complex,  time-consuming and <font color="blue">expensive process</font></td>
    </tr>
    <tr>
      <td>Before the merger, ATS and 3F operated  <font color="blue"><font color="blue">independent</font>ly</font>, each with its own business, products, customers, employees,  culture and systems</td>
    </tr>
    <tr>
      <td>ATS may experience material <font color="blue"><font color="blue">unanticipated</font> <font color="blue">difficult</font>ies</font> or  expenses in <font color="blue">connection with</font> the <font color="blue">integration</font> of 3F due to <font color="blue">various factors</font></td>
    </tr>
    <tr>
      <td>These  <font color="blue">factors may</font> include:         -    retaining and <font color="blue">integrating <font color="blue">management</font></font> and other <font color="blue">key employees</font> of the            <font color="blue">combined company</font>;         -    costs and delays in <font color="blue">implementing common systems</font> and procedures and            integrating 3Fapstas products and <font color="blue">operations</font> into ATSapstas business;                                             14    <PAGE>         -    potential charges to earnings resulting from the <font color="blue">application</font> of            <font color="blue">purchase accounting</font> to the <font color="blue">transaction</font>;         -    <font color="blue"><font color="blue">difficult</font>y comparing financial</font> reports due to <font color="blue">differing financial</font> and            <font color="blue">accounting systems</font>;         -    diversion of <font color="blue"><font color="blue"><font color="blue">management</font> resources</font> from</font> the business of the combined            company; and         -    reduction or loss of <font color="blue">customer sales due</font> to the potential for market            confusion, hesitation and delay</td>
    </tr>
    <tr>
      <td>The time and  <font color="blue">expense associated with converting</font> the <font color="blue">businesses</font> of the <font color="blue">combined company</font> to a  single <font color="blue">combined company</font> may exceed <font color="blue">management</font>apstas <font color="blue">expectation</font>s and limit or delay  the <font color="blue">intended benefits</font> of the <font color="blue">transaction</font></td>
    </tr>
    <tr>
      <td>To the extent any of these events  occurs, the benefits of the <font color="blue">transaction</font> may be reduced, at least for a period of  time</td>
    </tr>
    <tr>
      <td>In addition, it is possible that unexpected <font color="blue">transaction</font> costs, such as  taxes, fees or <font color="blue">professional expenses</font>, or <font color="blue">unexpected future</font> operating expenses,  such as increased personnel costs, as well as other types of <font color="blue">unanticipated</font>  adverse <font color="blue">developments</font>, could have a material adverse effect on ATSapstas business,  <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>IF THE CONDITIONS TO THE MERGER ARE NOT MET, THE MERGER MAY NOT OCCUR    Certain <font color="blue"><font color="blue">conditions</font> set forth</font> in the merger <font color="blue">agreement</font> must be satisfied or waived  to complete the merger</td>
    </tr>
    <tr>
      <td>If the <font color="blue">conditions</font> are not satisfied or waived, the  merger will not occur or will be delayed, and each of ATS and 3F may lose some  or all of the <font color="blue">intended benefits</font> of the merger</td>
    </tr>
    <tr>
      <td>In addition to other customary  closing <font color="blue">conditions</font>, the following <font color="blue">conditions</font> must be satisfied or waived, if  permissible, before ATS and 3F are obligated to complete the merger:         -    the issuance of the shares in the <font color="blue">merger must</font> be <font color="blue">approved by</font> the            <font color="blue">shareholders</font> of ATS; and         -    there must be no fact, event or circumstance that would have a            material adverse effect on the business of ATS or 3F, taken as a            whole</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that these <font color="blue">conditions</font> will be satisfied</td>
    </tr>
    <tr>
      <td>IN 2002, WE BEGAN USING A COMBINATION OF DIRECT SALES PERSONS AND INDEPENDENT  MANUFACTURING REPRESENTATIVES TO SELL OUR VALVES IN THE UNITED STATES IF OUR  US SALES STRATEGY IS NOT SUCCESSFUL, WE WILL NOT BE ABLE TO CONTINUE OUR  OPERATIONS AS PLANNED    Our sales approach for the sale <font color="blue">of the ATS </font>valve in the <font color="blue"><font color="blue">United States</font> </font>consists  primarily of <font color="blue">direct salespersons with</font> a few <font color="blue">independent</font> <font color="blue">manufacture</font>rapstas  <font color="blue">representatives</font></td>
    </tr>
    <tr>
      <td>We will need to continue to <font color="blue">expend <font color="blue">significant</font> funds</font> and  <font color="blue"><font color="blue">management</font> resources</font> to develop and maintain this <font color="blue"><font color="blue">hybrid sales</font> force</font></td>
    </tr>
    <tr>
      <td>We believe  there is <font color="blue"><font color="blue">significant</font> competition</font> for <font color="blue">sales personnel</font> and <font color="blue">independent</font>  <font color="blue">manufacturing</font> <font color="blue">representatives</font> with the <font color="blue">advanced sales skills</font> and technical  knowledge we need</td>
    </tr>
    <tr>
      <td>If we are unable to recruit, retain and <font color="blue">motivate qualified</font>  personnel and <font color="blue">representatives</font>, US sales <font color="blue">of the ATS </font><font color="blue">valve could</font> be <font color="blue">adversely</font>  affected</td>
    </tr>
    <tr>
      <td>The loss of <font color="blue">key salespersons</font> or <font color="blue">independent</font> <font color="blue">manufacture</font>rapstas  <font color="blue">representatives</font> could have a material adverse effect on our sales or potential  sales to <font color="blue">current customers</font> and <font color="blue">prospects serviced by such salespersons</font> or  <font color="blue">representatives</font></td>
    </tr>
    <tr>
      <td>Further, we <font color="blue">cannot assure</font> the <font color="blue">successful expansion</font> of our  network of <font color="blue">independent</font> <font color="blue">manufacture</font>rapstas <font color="blue">representatives</font> on terms acceptable to  ATS, if at all, or the <font color="blue">successful marketing</font> of our <font color="blue">products by</font> our <font color="blue">hybrid sales</font>  force</td>
    </tr>
    <tr>
      <td>To the extent we rely on sales through <font color="blue">independent</font> <font color="blue">manufacture</font>rapstas  <font color="blue">representatives</font>, any revenues we receive <font color="blue">will depend primarily on</font> the efforts of  these parties</td>
    </tr>
    <tr>
      <td>We do not control the amount and timing of <font color="blue">marketing resources</font>  that these <font color="blue">third parties devote</font> to our product</td>
    </tr>
    <tr>
      <td>If our US <font color="blue">sales strategy</font> is  not successful, we may be forced to change our US <font color="blue">sales strategy</font> again</td>
    </tr>
    <tr>
      <td>Any  such change <font color="blue">could disrupt sales</font> in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>Further, any change in our  US <font color="blue">sales strategy</font> could be expensive and <font color="blue">would likely</font> have a material adverse  <font color="blue">impact on</font> our results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>15    <PAGE>    WE CURRENTLY DEPEND ON THE MARKETING AND SALES EFFORTS OF INTERNATIONAL  INDEPENDENT DISTRIBUTORS, AND OUR SALES HAVE BEEN CONCENTRATED IN THREE  COUNTRIES    The ATS <font color="blue">heart valve</font> is sold <font color="blue">international</font>ly through <font color="blue">independent</font> distributors</td>
    </tr>
    <tr>
      <td>The loss of an <font color="blue">international</font> distributor could <font color="blue">seriously harm</font> our business and  results of <font color="blue">operations</font> if a <font color="blue">new distributor could</font> not be found on a <font color="blue">timely basis</font>  in the <font color="blue">relevant geographic market</font></td>
    </tr>
    <tr>
      <td>We do not control the amount and timing of  <font color="blue">marketing resources</font> that these <font color="blue">third parties devote</font> to our product</td>
    </tr>
    <tr>
      <td>Furthermore,  to the extent we rely on sales through <font color="blue">independent</font> distributors, any revenues we  receive <font color="blue">will depend primarily on</font> the efforts of these parties</td>
    </tr>
    <tr>
      <td>WE ARE DEPENDENT UPON SALES OUTSIDE THE UNITED STATES, WHICH ARE SUBJECT TO A  NUMBER OF RISKS INCLUDING A DROP IN SALES DUE TO CURRENCY FLUCTUATIONS    For the year ended <font color="blue">December </font>31, 2005, almost 62prca of our net sales were derived  from <font color="blue">international</font> <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We expect that <font color="blue"><font color="blue">international</font> sales will account</font>  for a substantial majority of our <font color="blue">revenue until</font> the ATS <font color="blue">heart valve</font> receives  wider <font color="blue">market acceptance</font> from US customers</td>
    </tr>
    <tr>
      <td>Accordingly, any material decrease  in foreign sales may <font color="blue">materially</font> and <font color="blue"><font color="blue">adversely</font> affect</font> our results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We sell in US dollars to most of our <font color="blue">customers abroad</font></td>
    </tr>
    <tr>
      <td>An increase in the  value of the US dollar in relation to other currencies can and has <font color="blue">adversely</font>  affected our <font color="blue">sales outside</font> of the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>In <font color="blue">prior years</font>, the decrease in  sales was <font color="blue">due primarily</font> to the change in the value of the US <font color="blue">dollar against</font>  the Euro, <font color="blue">as well as competitor price pressure</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">dependence on</font> <font color="blue">sales outside</font>  of the <font color="blue"><font color="blue">United States</font> </font><font color="blue">will continue</font> to expose us to US <font color="blue">dollar currency</font>  <font color="blue">fluctuations</font> for the <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>Our future results of <font color="blue">operations</font> could also be <font color="blue">harmed by risks inherent</font> in doing  business in <font color="blue"><font color="blue">international</font> markets</font>, including:         -    unforeseen changes in <font color="blue"><font color="blue">regulatory</font> <font color="blue">requirements</font></font> and <font color="blue">government health</font>            programs;         -    <font color="blue">weaker <font color="blue">intellectual property</font> rights protection</font> in some countries;         -    <font color="blue">new export license <font color="blue">requirements</font></font>, changes in tariffs or trade            <font color="blue">restrictions</font>;         -    political and <font color="blue">economic instability</font> in our <font color="blue">target markets</font>; and         -    <font color="blue">greater <font color="blue">difficult</font>y</font> in <font color="blue">collecting payments from product sales</font></td>
    </tr>
    <tr>
      <td>Slow payment of <font color="blue">receivables by</font> our <font color="blue"><font color="blue">international</font> distributors</font>, or the occurrence  of any of the other <font color="blue">factors listed</font> above, <font color="blue">could harm</font> our ability to <font color="blue">successfully</font>  <font color="blue">commercialize</font> our <font color="blue">product <font color="blue">international</font>ly</font> and <font color="blue">could harm</font> our business</td>
    </tr>
    <tr>
      <td>WE HAVE A HISTORY OF NET LOSSES IF WE DO NOT HAVE NET INCOME IN THE FUTURE, WE  MAY BE UNABLE TO CONTINUE OUR OPERATIONS    We are not <font color="blue">currently profitable</font> and have a very limited history of  <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005, we had an <font color="blue">accumulated deficit</font> of dlra84dtta1  million</td>
    </tr>
    <tr>
      <td>We expect to incur <font color="blue">significant</font> expenses over the <font color="blue">next several years as</font>  we continue to devote substantial resources to the <font color="blue">commercialization</font> <font color="blue">of the ATS </font> <font color="blue">heart valve</font> in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>We will not <font color="blue">generate net income unless</font> we are  able to <font color="blue"><font color="blue">significant</font>ly increase revenue from</font> US sales</td>
    </tr>
    <tr>
      <td>If we continue to  <font color="blue">sustain losses</font>, we may not be able to continue our business as planned</td>
    </tr>
    <tr>
      <td>WE HAVE A HISTORY OF REGULARLY RAISING FUNDS AND INCURRING DEBT TO FUND NET  LOSSES IF OUR CURRENT CASH AND INVESTMENT BALANCES ARE INADEQUATE TO CARRY US  TO PROFITABILITY, WE MAY NEED TO RAISE EQUITY OR INCUR DEBT IN THE FUTURE    During the last three years, we have completed <font color="blue">financings</font> to fund our  <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If our future <font color="blue">operations</font> require <font color="blue">greater cash than</font> our current  balances, we would again be required to <font color="blue">raise equity</font> or issue debt</td>
    </tr>
    <tr>
      <td>16    <PAGE>    THE MARKET FOR PROSTHETIC HEART VALVES IS HIGHLY COMPETITIVE, AND A NUMBER OF  OUR COMPETITORS ARE LARGER AND HAVE MORE FINANCIAL RESOURCES IF WE DO NOT  COMPETE EFFECTIVELY, OUR BUSINESS WILL BE HARMED    The market for prosthetic <font color="blue">heart valve</font>s is <font color="blue">highly competitive</font></td>
    </tr>
    <tr>
      <td>We expect that  competition will intensify as additional companies enter the market or modify  their <font color="blue">existing products</font> to <font color="blue">compete directly with us</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">primary competitor</font>, St</td>
    </tr>
    <tr>
      <td>Jude Medical, Inc, currently controls approximately 50prca of the worldwide  mechanical <font color="blue">heart valve</font> market</td>
    </tr>
    <tr>
      <td>Many of our <font color="blue">competitors</font> have long-standing FDA  approval for their valves and extensive <font color="blue">clinical data demonstrating</font> the  performance of their valves</td>
    </tr>
    <tr>
      <td>In addition, they have <font color="blue">greater financial</font>,  <font color="blue">manufacturing</font>, marketing and research and <font color="blue">development capabilities than</font> we have</td>
    </tr>
    <tr>
      <td>For example, many of our <font color="blue">competitors</font> have the ability, due to their internal  <font color="blue">carbon <font color="blue">manufacturing</font> facilities</font> and economies of scale, to <font color="blue">manufacture</font> their  <font color="blue">heart valve</font>s at a <font color="blue">lower cost than</font> we can <font color="blue">manufacture</font> the ATS <font color="blue">heart valve</font></td>
    </tr>
    <tr>
      <td>Our  <font color="blue">primary competitor</font> has <font color="blue">recently used price as</font> a method to compete in several  <font color="blue"><font color="blue">international</font> markets</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">heart valve</font> prices decline <font color="blue">significant</font>ly we might not  be able to compete <font color="blue">successfully</font>, which would harm our results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>OUR FUTURE RESULTS WILL BE HARMED IF THE USE OF MECHANICAL HEART VALVES  DECLINES    Our business <font color="blue">could suffer</font> if the use of mechanical <font color="blue">heart valve</font>s declines</td>
    </tr>
    <tr>
      <td>Historically, mechanical <font color="blue">heart valve</font>s have accounted for over two-thirds of all  <font color="blue">heart valve</font> replacements</td>
    </tr>
    <tr>
      <td>Recently, there has been an increase in the use of  <font color="blue">tissue valves</font></td>
    </tr>
    <tr>
      <td>We estimate that mechanical <font color="blue">heart valve</font>s are currently being used  in 40prca to 65prca of all <font color="blue">heart valve</font> replacements, depending on the geographic  market, down from 65prca to 75prca about ten years ago</td>
    </tr>
    <tr>
      <td>We believe the tissue  <font color="blue">manufacture</font>rs &amp;apos  claims of <font color="blue">improvements</font> in <font color="blue">tissue valve longevity</font> and an increase  in the <font color="blue">average age</font> of <font color="blue">valve patients</font> have <font color="blue">contributed</font> to the <font color="blue">recent increase</font> in  the use of <font color="blue">tissue valves</font></td>
    </tr>
    <tr>
      <td>NEW PRODUCTS OR TECHNOLOGIES DEVELOPED BY OTHERS COULD RENDER OUR PRODUCT  OBSOLETE    The medical device industry is <font color="blue">characterized by <font color="blue">significant</font> technological</font>  advances</td>
    </tr>
    <tr>
      <td>Several companies are developing new prosthetic <font color="blue">heart valve</font>s based on  new or <font color="blue">potentially improved technologies</font></td>
    </tr>
    <tr>
      <td><font color="blue">Significant </font>advances are also being  made in <font color="blue">surgical procedure</font>s, which may delay the need for <font color="blue">replacement heart</font>  valves</td>
    </tr>
    <tr>
      <td>A new product or <font color="blue"><font color="blue">technology</font> may emerge</font> that renders the ATS <font color="blue">heart valve</font>  <font color="blue">noncompetitive</font> or obsolete</td>
    </tr>
    <tr>
      <td>This <font color="blue">could <font color="blue">materially</font></font> harm our results of <font color="blue">operations</font>  or force us to cease doing business <font color="blue">altogether</font></td>
    </tr>
    <tr>
      <td>WE LICENSE PATENTED TECHNOLOGY AND OTHER PROPRIETARY RIGHTS FROM CARBOMEDICS IF  THESE AGREEMENTS ARE BREACHED OR TERMINATED, OUR RIGHT TO MANUFACTURE THE ATS  HEART VALVE COULD BE TERMINATED    Under our carbon <font color="blue">technology</font> <font color="blue">agreement</font> with Carbomedics, we have obtained a  license to use <font color="blue">Carbomedics </font>&amp;apos  <font color="blue"><font color="blue">pyrolytic carbon</font> <font color="blue">technology</font></font> to <font color="blue">manufacture</font>  <font color="blue">components</font> for the ATS <font color="blue">heart valve</font></td>
    </tr>
    <tr>
      <td>If this <font color="blue">agreement</font> is breached or terminated,  we would be unable to <font color="blue">manufacture</font> our own product</td>
    </tr>
    <tr>
      <td>If our inventory is exhausted  and we do not have any other sources of carbon <font color="blue">components</font>, we would be forced to  cease doing business</td>
    </tr>
    <tr>
      <td>A DELAY OR INTERRUPTION IN OUR MANUFACTURING OF PYROLYTIC CARBON COMPONENTS  COULD DELAY PRODUCT DELIVERY OR FORCE US TO CEASE OPERATIONS    Although we have a supply <font color="blue">agreement</font> with <font color="blue">Carbomedics </font>under which it agrees to  <font color="blue">supply us with</font> a <font color="blue">minimum annual</font> number of <font color="blue">pyrolytic carbon</font> <font color="blue">components</font> starting  in 2007 continuing through 2011, the <font color="blue">amounts available under</font> this <font color="blue">agreement</font> are  not expected to be sufficient to supply all of our needs for <font color="blue">components</font> in those  years</td>
    </tr>
    <tr>
      <td>If our inventory is exhausted and we are unable to <font color="blue">manufacture</font> carbon  <font color="blue">components</font> or obtain them from other sources, we could be forced to reduce or  cease <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>BECAUSE WE LACK MANUFACTURING EXPERIENCE, WE MAY NOT REALIZE EXPECTED SAVINGS  FROM MANUFACTURING OUR OWN PRODUCT IN ADDITION, WE COULD EXPERIENCE PRODUCTION  DELAYS AND SIGNIFICANT ADDITIONAL COSTS    Under our <font color="blue">agreement</font> with Carbomedics, we have <font color="blue">been granted</font> an exclusive  <font color="blue">worldwide license</font> to <font color="blue">manufacture</font> <font color="blue">pyrolytic carbon</font> <font color="blue">components</font> for the ATS heart  valve</td>
    </tr>
    <tr>
      <td>We cannot be certain that our strategy to <font color="blue">establish internal</font>  <font color="blue">manufacturing</font> capabilities will result in a cost-effective means for  <font color="blue">manufacturing</font> the ATS <font color="blue">heart valve</font></td>
    </tr>
    <tr>
      <td>We have limited experience in <font color="blue">manufacturing</font>  <font color="blue">pyrolytic carbon</font></td>
    </tr>
    <tr>
      <td>Although we have an FDA-approved carbon <font color="blue">manufacturing</font>  <font color="blue">facility</font>, we have <font color="blue">only just started increasing production</font> to <font color="blue">higher levels</font></td>
    </tr>
    <tr>
      <td>In  the future, as we continue to increase                                             17    <PAGE>    <font color="blue">production at</font> the plant, we may <font color="blue">encounter <font color="blue">difficult</font>ies</font> in maintaining and  expanding our <font color="blue">manufacturing</font> <font color="blue">operations</font>, including <font color="blue">problems involving</font>:         -    <font color="blue">production yields</font>;         -    <font color="blue">quality control</font>;         -    per unit <font color="blue">manufacturing</font> costs;         -    shortages of <font color="blue">qualified personnel</font>; and         -    <font color="blue">compliance with</font> FDA and <font color="blue">international</font> <font color="blue">regulations</font> and <font color="blue">requirements</font>            regarding good <font color="blue">manufacturing</font> practices</td>
    </tr>
    <tr>
      <td><font color="blue">Difficulties </font><font color="blue">encountered by us</font> in <font color="blue">establishing</font> or maintaining a commercial-scale  <font color="blue">manufacturing</font> <font color="blue">facility</font> may limit our ability to <font color="blue">manufacture</font> our <font color="blue">heart valve</font> and  <font color="blue">therefore could <font color="blue">seriously harm</font></font> our business and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>OUR BUSINESS COULD BE SERIOUSLY HARMED IF THIRD-PARTY PAYERS DO NOT REIMBURSE  THE COSTS FOR OUR HEART VALVE    Our ability to <font color="blue">successfully</font> <font color="blue">commercialize</font> the ATS <font color="blue">heart valve</font> depends on the  extent to <font color="blue">which <font color="blue">reimbursement</font></font> for the cost of our product and the related  <font color="blue">surgical procedure</font> is available from third-party payers, such as governmental  programs, private insurance plans and <font color="blue">managed care organizations</font></td>
    </tr>
    <tr>
      <td>Third-party  payers are <font color="blue">increasingly challenging</font> the pricing of <font color="blue">medical products</font> and  procedures that they consider not to be cost-effective or are used for a  non-approved indication</td>
    </tr>
    <tr>
      <td>The failure by physicians, hospitals and other users of  our products to obtain sufficient <font color="blue">reimbursement</font> from third-party payers would  <font color="blue">seriously harm</font> our business and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In recent years, there have <font color="blue">been numerous proposals</font> to change the <font color="blue">health care</font>  system in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>Some of these proposals have included measures that  would limit or eliminate payment for medical procedures or <font color="blue">treatments</font></td>
    </tr>
    <tr>
      <td>In  addition, government and private third-party payers are <font color="blue">increasingly attempting</font>  to contain <font color="blue">health care</font> costs by limiting both the coverage and the level of  <font color="blue">reimbursement</font></td>
    </tr>
    <tr>
      <td>In <font color="blue"><font color="blue">international</font> markets</font>, <font color="blue">reimbursement</font> and <font color="blue">health care</font> payment  <font color="blue">systems vary <font color="blue">significant</font>ly by country</font></td>
    </tr>
    <tr>
      <td>In addition, we have <font color="blue">encountered price</font>  resistance from government-administered health programs</td>
    </tr>
    <tr>
      <td><font color="blue">Significant </font>changes in  the <font color="blue">health care</font> system in the <font color="blue"><font color="blue">United States</font> </font>or elsewhere, including changes  resulting from adverse trends in third-party <font color="blue">reimbursement</font> programs, could have  a material adverse effect on our business and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>WE MAY FACE PRODUCT LIABILITY CLAIMS, WHICH COULD RESULT IN LOSSES IN EXCESS OF  OUR INSURANCE COVERAGE AND WHICH COULD NEGATIVELY AFFECT OUR ABILITY TO ATTRACT  AND RETAIN CUSTOMERS    The <font color="blue">manufacture</font> and sale of mechanical <font color="blue">heart valve</font>s entails <font color="blue">significant</font> risk of  <font color="blue">product <font color="blue">liability</font></font> claims and <font color="blue"><font color="blue">product recall</font>s</font></td>
    </tr>
    <tr>
      <td>A mechanical <font color="blue">heart valve</font> is a  life-sustaining device and the failure of any mechanical <font color="blue">heart valve</font> usually  results in the patientapstas death or need for re-operation</td>
    </tr>
    <tr>
      <td>A <font color="blue">product <font color="blue">liability</font></font>  claim or <font color="blue">product recall</font>, regardless of the ultimate outcome, could require us to  <font color="blue">spend <font color="blue">significant</font></font> time and money in <font color="blue">litigation</font> or to <font color="blue">pay <font color="blue">significant</font> damages</font> and  could <font color="blue">seriously harm</font> our business</td>
    </tr>
    <tr>
      <td>We currently maintain <font color="blue">product <font color="blue">liability</font></font>  <font color="blue">insurance coverage</font> in an <font color="blue">aggregate amount</font> of dlra25 million</td>
    </tr>
    <tr>
      <td>However, we cannot be  assured that our current <font color="blue">insurance coverage</font> is adequate to cover the costs of  any <font color="blue">product <font color="blue">liability</font></font> claims made <font color="blue">against us</font></td>
    </tr>
    <tr>
      <td>Product <font color="blue"><font color="blue">liability</font> insurance</font> is  expensive and does not cover the costs of a <font color="blue">product recall</font></td>
    </tr>
    <tr>
      <td>In the future,  <font color="blue">product <font color="blue">liability</font></font> insurance may not be available at satisfactory rates or in  <font color="blue">adequate amounts</font></td>
    </tr>
    <tr>
      <td>A <font color="blue">product <font color="blue">liability</font></font> claim or <font color="blue">product recall</font> could also  <font color="blue">materially</font> and <font color="blue"><font color="blue">adversely</font> affect</font> our ability to attract and retain customers</td>
    </tr>
    <tr>
      <td>OUR BUSINESS WOULD BE ADVERSELY AFFECTED IF WE ARE NOT ABLE TO PROTECT OUR  INTELLECTUAL PROPERTY RIGHTS    Our <font color="blue">success depends</font> in part on our ability to maintain and enforce our patents  and other <font color="blue"><font color="blue">proprietary</font> rights</font></td>
    </tr>
    <tr>
      <td>We rely on a <font color="blue">combination</font> of patents, trade  secrets, know-how and confidentiality <font color="blue">agreement</font>s to protect the <font color="blue">proprietary</font>  aspects of our <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">measures afford only</font> limited protection, and  <font color="blue">competitors</font> may gain access to our <font color="blue">intellectual property</font> and <font color="blue">proprietary</font>  information</td>
    </tr>
    <tr>
      <td>The <font color="blue">patent positions</font> of medical device companies are <font color="blue">generally</font>  uncertain and <font color="blue">involve complex legal</font> and <font color="blue">technical issues</font></td>
    </tr>
    <tr>
      <td><font color="blue">Litigation </font>may be  <font color="blue">necessary</font> to enforce our <font color="blue">intellectual property</font> rights, to protect our trade  secrets and to determine the validity and scope of our <font color="blue"><font color="blue">proprietary</font> rights</font></td>
    </tr>
    <tr>
      <td>Any  <font color="blue">litigation</font> could be costly and divert our <font color="blue">attention from</font> the growth of the  business</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that our patents and other <font color="blue"><font color="blue">proprietary</font> rights</font>  will not be <font color="blue">successfully</font> challenged, or that <font color="blue">others will</font> not <font color="blue"><font color="blue">independent</font>ly</font>  develop <font color="blue">substantially equivalent</font> information and <font color="blue">technology</font> or <font color="blue">otherwise gain</font>  access to our <font color="blue">proprietary</font> <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>18    <PAGE>    WE MAY BE SUED BY THIRD PARTIES WHICH CLAIM THAT OUR PRODUCT INFRINGES ON THEIR  INTELLECTUAL PROPERTY RIGHTS ANY SUCH SUITS COULD RESULT IN SIGNIFICANT  LITIGATION OR LICENSING EXPENSES OR WE MIGHT BE PREVENTED FROM SELLING OUR  PRODUCT    We may be exposed to future <font color="blue">litigation</font> by third parties based on intellectual  <font color="blue">property infringement</font> claims</td>
    </tr>
    <tr>
      <td>Any claims or <font color="blue">litigation</font> <font color="blue">against us</font>, regardless of  the merits, could result in substantial costs and <font color="blue">could harm</font> our business</td>
    </tr>
    <tr>
      <td>In  addition, <font color="blue">intellectual property</font> <font color="blue">litigation</font> or claims <font color="blue">could force us</font> to:         -    cease <font color="blue">manufacturing</font> and selling our product, which would seriously            harm us;         -    obtain a <font color="blue">license from</font> the holder of the <font color="blue">infringed intellectual</font>            property right, <font color="blue">which license may</font> not be <font color="blue">available on reasonable</font>            terms, if at all; or         -    redesign our product, which could be costly and time-consuming</td>
    </tr>
    <tr>
      <td>WE ARE SUBJECT TO EXTENSIVE GOVERNMENTAL REGULATION, WHICH IS COSTLY, TIME  CONSUMING AND CAN SUBJECT US TO UNANTICIPATED DELAYS    The ATS <font color="blue">heart valve</font> and our <font color="blue">manufacturing</font> activities are subject to extensive  <font color="blue">regulation by</font> a number of <font color="blue">governmental agencies</font>, including the FDA and  comparable <font color="blue">international</font> agencies</td>
    </tr>
    <tr>
      <td>We are required to:         -    maintain the approval of the FDA and <font color="blue">international</font> <font color="blue">regulatory</font> agencies            to continue selling the ATS <font color="blue">heart valve</font>;         -    obtain the approval of <font color="blue">international</font> <font color="blue">regulatory</font> agencies in countries            where the ATS <font color="blue">heart valve</font> is not yet marketed;         -    satisfy content <font color="blue">requirements</font> for all of our labeling, sales and            <font color="blue">promotional materials</font>;         -    comply with <font color="blue">manufacturing</font> and reporting <font color="blue">requirements</font>; and         -    <font color="blue">undergo rigorous inspections by</font> these agencies</td>
    </tr>
    <tr>
      <td><font color="blue">Compliance </font>with the <font color="blue">regulations</font> of these <font color="blue">agencies may delay</font> or <font color="blue">prevent us from</font>  introducing any new or <font color="blue">improved products</font></td>
    </tr>
    <tr>
      <td><font color="blue">Violations </font>of <font color="blue"><font color="blue">regulatory</font> <font color="blue">requirements</font></font>  may result in fines, marketing <font color="blue">restrictions</font>, <font color="blue">product recall</font>, withdrawal of  approvals and civil and criminal penalties</td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> of our <font color="blue"><font color="blue">common stock</font> could</font> be <font color="blue">impacted by</font> the following:         -    the success of our <font color="blue">management</font> in operating ATS <font color="blue">effectively</font>;         -    the failure <font color="blue">of the ATS </font>valve to gain <font color="blue">market acceptance</font> in the United            States;         -    <font color="blue">announcements</font> of <font color="blue">technical innovations</font> or new <font color="blue">products by</font> our            <font color="blue">competitors</font>;         -    the status of component <font color="blue">supply arrangements</font>;         -    changes in <font color="blue">reimbursement</font> policies;         -    <font color="blue">government regulation</font>;         -    <font color="blue">developments</font> in patent or other <font color="blue"><font color="blue">proprietary</font> rights</font>;         -    public concern as to the safety and efficacy of products developed by            us or others; and         -    general market <font color="blue">conditions</font></td>
    </tr>
    <tr>
      <td>In addition, due to one or more of the <font color="blue">foregoing factors</font>, in <font color="blue">future years</font> our  results of <font color="blue">operations</font> may fall below the <font color="blue">expectation</font>s of <font color="blue">securities analysts</font> and  investors</td>
    </tr>
    <tr>
      <td>In that event, the <font color="blue">market price</font> of our <font color="blue"><font color="blue">common stock</font> could</font> be  <font color="blue">materially</font> and <font color="blue"><font color="blue">adversely</font> affect</font>ed</td>
    </tr>
    <tr>
      <td>Finally, in recent years the stock market has  experienced extreme price and                                             19    <PAGE>    volume <font color="blue">fluctuations</font></td>
    </tr>
    <tr>
      <td>This <font color="blue">volatility</font> has had a <font color="blue">significant</font> effect on the market  prices of <font color="blue">securities issued by</font> many companies for <font color="blue">reasons unrelated</font> to their  operating performance</td>
    </tr>
    <tr>
      <td>These broad market <font color="blue">fluctuations</font> may <font color="blue">materially</font> <font color="blue">adversely</font>  affect our stock price, regardless of our operating results</td>
    </tr>
    <tr>
      <td>OUR CHARTER DOCUMENTS AND MINNESOTA LAW MAY DISCOURAGE AND COULD DELAY OR  PREVENT A TAKEOVER OF OUR COMPANY    Provisions of our articles of <font color="blue">incorporation</font>, bylaws <font color="blue">and <font color="blue">Minnesota </font></font>law could make  it more <font color="blue">difficult</font> for a <font color="blue">third party</font> to acquire us, even if doing so would be  <font color="blue">beneficial</font> to our <font color="blue">shareholders</font></td>
    </tr>
    <tr>
      <td>These provisions include the following:         -    No cumulative voting by <font color="blue">shareholders</font> for <font color="blue">directors</font>;         -    The ability of our board to set the size of the board of <font color="blue">directors</font>, to            create new <font color="blue">directors</font>hips and to <font color="blue">fill vacancies</font>;         -    The ability of our board, without shareholder approval, to issue            preferred stock, which may have rights and <font color="blue">preferences</font> that are            superior to our <font color="blue">common stock</font>;         -    The ability of our board to amend the bylaws; and         -    <font color="blue">Restrictions </font>under <font color="blue">Minnesota </font><font color="blue">law on mergers</font> or other business            <font color="blue">combination</font>s between us and any holder of 10prca or more of our            outstanding <font color="blue">common stock</font></td>
    </tr>
  </tbody>
</table>